NF-κB localization in multiple myeloma plasma cells and mesenchymal cells

Concetta Conticello, Raffaella Giuffrida, Luana Adamo, Gabriele Anastasi, Daniela Martinetti, Edvige Salomone, Cristina Colarossi, Gabriella Amato, Ausilia Gorgone, Alessandra Romano, Gioacchin Iannolo, Ruggero De Maria, Rosario Giustolisi, Massimo Gulisano, Francesco Di Raimondo

Research output: Contribution to journalArticlepeer-review


Several reports demonstrated that the activation of Nuclear Factor-kappa B NF-κB is essential for the pathogenesis of multiple myeloma (MM). We analyzed the nuclear localization of NF-κB in MM-cells derived from 60 different patients with MM at presentation and in relapse, as well as in three myeloma cell lines. Nuclear localization (the active form) of NF-κB was detected in only one MM-sample from a refractory patient and in two samples from relapsed patients, while all the other samples, including the MM-cell lines, almost exclusively express the cytoplasmic (inactive) form of NF-κB. In mesenchymal cells from MM-patients NF-κB was clearly present in the nucleus. In addition, the proteasome inhibitor Bortezomib, which is described to antagonize NF-κB activity, had a consistent antitumor activity against both chemoresistant and chemosensitive MM-cells, regardless the NF-κB localization, thus suggesting the existence of other molecular targets of proteasome inhibitors in MM.

Original languageEnglish
Pages (from-to)52-60
Number of pages9
JournalLeukemia Research
Issue number1
Publication statusPublished - Jan 2011


  • Bortezomib
  • Mesenchymal cells
  • Multiple myeloma
  • NF-κB

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology


Dive into the research topics of 'NF-κB localization in multiple myeloma plasma cells and mesenchymal cells'. Together they form a unique fingerprint.

Cite this